Multicentre retrospective series indicate that, among women with HER2-enriched breast carcinoma who receive preoperative trastuzumab plus pertuzumab, roughly 1–3% percent develop intracranial metastasis as the earliest and sole site of relapse within two years, independent of pCR status (18). Here, ERBB2 is linked to breast carcinoma.